Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 1.1458
-6.25 %
$ 7.8 M
Market Cap
10.0
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart INBS
FINANCIALS
Balance Sheet
Intelligent Bio Solutions Inc.
| Current Assets | 8.53 M |
| Cash & Short-Term Investments | 6.3 M |
| Receivables | 978 K |
| Other Current Assets | 1.25 M |
| Non-Current Assets | 5.24 M |
| Long-Term Investments | 0 |
| PP&E | 873 K |
| Other Non-Current Assets | 4.37 M |
| Current Liabilities | 5.45 M |
| Accounts Payable | 602 K |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.78 M |
| Non-Current Liabilities | 145 K |
| Long-Term Debt | 81.3 K |
| Other Non-Current Liabilities | 63.6 K |
EFFICIENCY
Earnings Waterfall
Intelligent Bio Solutions Inc.
| Revenue | 3.11 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.43 M |
| Operating Expenses | 11.7 M |
| Operating Income | -10.3 M |
| Other Expenses | -92.2 K |
| Net Income | -10.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intelligent Bio Solutions Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 1.21 M |
| Capital Expenditures | -221 K |
| Stock-Based Compensation | 230 K |
| Change in Working Capital | -702 K |
| Others | -258 K |
| Free Cash Flow | -9.79 M |
Wall Street Analysts Price Targets
Intelligent Bio Solutions Inc.
INBS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
INBS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Intelligent Bio Solutions Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabic, Italian, and Spanish. This rollout supports the Company's global growth plans and international sales expansion by opening digital and commercial access to some of the world's fastest-growing, high-demand regions for workplace safety and compliance solutions.
globenewswire.com
- 2 weeks ago
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
globenewswire.com
- 4 weeks ago
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade. The addition of Arabic follows INBS's previously announced expansion plans in the Middle East in early 2025, through its partnership with Ivy Diagnostics.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the International Symposium on Tuesday, April 1, at 1:00 PM.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
zacks.com
- 1 month ago
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a strategic collaboration with Detecto, a division of Spanish distributor MTB Distribuciones Tecnologicas SL ("MTB"). MTB established Detecto following decades of experience in clinical distribution, recognizing the market's evolving needs and increasing demand for drug testing across various sectors.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
globenewswire.com
- 1 month ago
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for launch in the U.S. in 2025 targeting its opiate test system for codeine, as validated in the Company's Pharmacokinetic (PK) study. On December 18, 2024, the Company announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System, which the FDA classified as a 21 CFR 862.3650, Opiate Test System, a Class II device requiring submission of a 510(k) premarket notification.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting Drug Testing Solution.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter's Option to Purchase Additional Shares of Common Stock
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock, which included the full exercise of the underwriter's option to purchase up to 195,652 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $3.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offering expenses.
globenewswire.com
- 2 months ago
8. Profile
Summary
Intelligent Bio Solutions Inc. INBS
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 7.8 M
Dividend Yield
0.00%
Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Contact
142 West 57th Street, New York, NY, 10019
https://gbs.inc
IPO
Date
Dec. 23, 2020
Employees
50
Officers
Anna Turkington
Vice President of Marketing
Mr. Doug Heath
Vice President of Global Sales
Callistus Sequeira
Vice President of Global Quality & Operations
Mr. Harry Simeonidis
President & Chief Executive Officer
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law
Chief Financial Officer